Previous 10 | Next 10 |
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 ...
2023-08-02 17:35:58 ET Natera ( NASDAQ: NTRA ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, after market close. The consensus EPS Estimate is -$1.10 and the consensus Revenue Estimate is $241.53M (+21.9% Y/Y). Over the last 1 year, NTRA has b...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA. A live webcast and audio archive of t...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ("NeoGenomics") for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics...
Study to evaluate clinical utility of ctDNA-guided treatment escalation for CRC patients; results expected to read out in mid-2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phas...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
2023-07-17 17:38:24 ET Genetic testing company Natera ( NASDAQ: NTRA ) said on Monday that a Delaware court issued a decision in its favor in the false advertising lawsuit brought by rival CareDx ( NASDAQ: CDNA ). The Austin-based company said that the Delaware cour...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware issued a decision in favor of Natera in the false advertising case brought by CareDx, Inc. In today’s decision, the Court reversed fin...
2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...
2023-07-07 10:45:34 ET Update 10:45 AM EST: Adds comments from Craig Hallum Diagnostics firm Castle Biosciences ( NASDAQ: CSTL ) added ~41% in the morning hours Friday in a move attributed to an unexpected policy reversal regarding Medicare coverage for the company’s ...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA. A live webcast and audio archive of...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...